Alopecia areata (AA) is a disease that affects both men and women, with an overall
prevalence of 1.2% to 2.2%. 1, 2 A strong connection has been reported between AA and …

Background Alopecia areata (AA) is an autoimmune hair loss disorder characterised by
collapse of hair follicle immune privilege and mediated by autoreactive CD8+ T lymphocytes …

Alopecia areata (AA) is an autoimmune disease with a complex pathophysiology resulting in
nonscarring hair loss in genetically susceptible individuals. We aim to provide health care …

Objectives To provide evidence about effectiveness and safety of tofacitinib and baricitinib in
AA in real-world settings and describe baseline disease characteristics and patients profiles …

Background A set of criteria for severity classification is essential in alopecia areata (AA).
Currently, no guidelines are universally accepted for defining AA severity. Objective This …

Introduction: Diphenylcyclopropenone (DPCP) is the medication of choice for the treatment
of severe alopecia areata (AA) according to AA treatment guidelines. Precise initiation and …

Objective Alopecia areata (AA) is often characterized by sudden onset of patchy hair loss.
Topical corticosteroid injection is the most common treatment. This study retrospectively …

Introduction Alopecia areata (AA) is an autoimmune disease characterized by nonscarring
hair loss involving the scalp, face, and/or body. Literature on the prevalence, patient …

Objective Alopecia areata (AA) is a prevalent autoimmune disorder characterized by hair
loss triggered by inflammation. Platelet-rich plasma (PRP) has recently gained attention as a …

Human amniotic fluid stem cell (hAFSC) exhibit significantly as a new treatment modality in
hair loss, wound, scar and regenerative plastic surgery/dermatology. The difference of our …